<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966143</url>
  </required_header>
  <id_info>
    <org_study_id>LY011C1001</org_study_id>
    <nct_id>NCT04966143</nct_id>
  </id_info>
  <brief_title>Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer</brief_title>
  <official_title>A Study of CLDN18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Longyao Biotechnology Inc., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Longyao Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLDN 18.2 chimeric antigen receptor T cells Clinical research plan for the treatment of&#xD;
      recurrent or refractory pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response rate（ORR）</measure>
    <time_frame>1month</time_frame>
    <description>the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>1 years</time_frame>
    <description>Survival witouth observed progression at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate（DCR）</measure>
    <time_frame>1 years</time_frame>
    <description>DCR (CR+PR+SD) by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR）</measure>
    <time_frame>1 years</time_frame>
    <description>DOR was defined as the time from the first documented a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) to progressive disease (PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overal survival （OS）</measure>
    <time_frame>5 years</time_frame>
    <description>survival at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>1 year</time_frame>
    <description>AEs according to CTCAE v 5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY011</intervention_name>
    <description>Targeting CLDN 18.2 Car-T injection</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  They were 18 to 70 years old, male or female;&#xD;
&#xD;
          -  Definitive diagnosis is recurrent or refractory pancreatic cancer;&#xD;
&#xD;
          -  Claudin 18.2 IHC staining was positive in tumor tissues;&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks;&#xD;
&#xD;
          -  According to RECIST 1.1, there was at least one measurable tumor target;&#xD;
&#xD;
          -  ECoG scores at screening, 24 hours before puncture and baseline (before treatment)&#xD;
             were 0-1;&#xD;
&#xD;
          -  Adequate organ function;&#xD;
&#xD;
          -  Women of childbearing age with negative pregnancy test or male subjects must take&#xD;
             effective and reliable contraceptive methods until 30 days after the end of treatment;&#xD;
&#xD;
          -  Have enough understanding ability to voluntarily sign informed consent to participate&#xD;
             in clinical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  HIV, syphilis spirochete or HCV serological positive;&#xD;
&#xD;
          -  Any uncontrollable active infection, including but not limited to active tuberculosis,&#xD;
             HBV infection (HBsAg positive, HBcAb positive, HBV DNA positive);&#xD;
&#xD;
          -  The subjects were judged as clinically significant thyroid dysfunction by the&#xD;
             investigators (serum thyroid hormone determination TT4, TT3, FT3, FT4, serum thyroid&#xD;
             stimulating hormone TSH) and were not suitable to participate in this study;&#xD;
&#xD;
          -  The side effects of the patients were not recovered to CTCAE ≤ 1;&#xD;
&#xD;
          -  Subjects who are currently using steroids all over the body within 7 days before the&#xD;
             pregnancy is taken out; Inhaled steroids are not excluded in the near future or in the&#xD;
             near future;&#xD;
&#xD;
          -  Previous allergies to immunotherapy and related drugs, severe allergies or allergies;&#xD;
&#xD;
          -  T cells (including car-t, tcr-t) that have been modified by chimeric antigen receptor&#xD;
             have been reported.&#xD;
&#xD;
          -  The subjects had untreated or symptomatic brain metastasis;&#xD;
&#xD;
          -  The subjects had heart disease which needed treatment or after treatment, hypertension&#xD;
             was out of control (blood pressure &gt; 160 mmHg / 100 mmHg);&#xD;
&#xD;
          -  Subjects with or waiting for organ transplantation history;&#xD;
&#xD;
          -  No other serious disease may limit subjects' participation in this trial&#xD;
&#xD;
          -  The researchers assessed that subjects were unable or unwilling to comply with the&#xD;
             requirements of the study program.&#xD;
&#xD;
          -  It has abnormal signs of central nervous system diseases or abnormal results of&#xD;
             nervous system detection, which has clinical significance;&#xD;
&#xD;
          -  Subjects currently or had other malignant tumors that could not be cured within 3&#xD;
             years, except for in situ cervical or skin basal cell carcinoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
      <phone>0516-85802369</phone>
      <email>xyfyll2297@163.com</email>
    </contact>
    <investigator>
      <last_name>Bin Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenxing Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

